A Phase IV Clinical Trial of Patients with Solid Tumors Receiving Lenograstim as Primary Prophylaxis for Chemotherapy-Induced Neutropenia, in a Docetaxel-Based Regimen

Table 1

Patient and cancer baseline characteristics.

Baseline characteristic	Number of patients (%)
Sex
Male	49 (12)
Female	345 (88)
Age (years)
Median	54
Range	26–88
ECOG performance status
Grade 0	232 (58.9)
Grade 1	128 (32.5)
Grade 2	11 (2.8)
Grade 3	1 (0.3)
Grade 4	0
Unknown	22 (5.6)
Breast cancer	318 (80.7)
Non-small cell lung cancer	14 (3.6)
Ovarian cancer	14 (3.6)
Hormone refractory prostate cancer	18 (4.6)
Nonhormone refractory prostate cancer	6 (1.5)
Gastric cancer	14 (3.5)
Head and neck cancer	10 (2.4)

The percentage is calculated out of the 394, the total number of patients in the study’s cohort for sex, age, ECOG status, and cancer type.